癌症患者的肌肉减少症与复杂的术后结果相关。本研究的目的是评估新辅助治疗期间肌肉减少症的发生是否可以预测食管腺癌患者的术后死亡率。我们查询了前瞻性数据库，以检索接受横断面成像的食管腺癌患者的肌肉减少症状态。诊断时以及 2014 年至 2022 年间接受食管胃切除术后 2 个月内的第三腰椎。在该研究纳入的 71 名患者中，36 名 (50.7%) 在诊断时出现肌少症。在 35 名非肌肉减少症患者中，14 名（40%）在新辅助治疗期间出现肌肉减少症。诊断时未出现肌少症但术前出现肌少症的患者的总生存期明显低于诊断时患有肌少症且术前未出现肌少症的患者以及肌少症状态无变化的患者（中位时间 18 个月与 47 个月与 31 个月；P = .02）。仅诊断和术前肌少症状态与总生存率没有显着相关（分别为 P = .48 和 P = .56）。尽管有 37 名患者（52.1%）死亡，但死因通常与癌症无关（54.1%），包括急性呼吸衰竭、肺炎和心脏骤停。当按 >10% 体重减轻 (P = .9) 或体重指数大幅下降 (P = .8) 进行分层时，未观察到显着的生存差异。新辅助治疗期间出现肌少症可能与较差的总生存率相关需要食管胃切除术的患者。版权所有 © 2023 Elsevier Inc. 保留所有权利。

Sarcopenia in cancer patients has been associated with mixed postoperative outcomes. The aim of this study was to evaluate whether the development of sarcopenia during the neoadjuvant period is predictive of postoperative mortality in esophageal adenocarcinoma patients.We queried a prospective database to retrieve the sarcopenic status of patients with esophageal adenocarcinoma who underwent cross-sectional imaging of the third lumbar vertebra at diagnosis and within 2 months of undergoing an esophagogastrectomy between 2014 and 2022.Of the 71 patients included in the study, 36 (50.7%) presented with sarcopenia at diagnosis. Of the 35 non-sarcopenic patients, 14 (40%) developed sarcopenia during the neo-adjuvant period. Patients who were not sarcopenic at diagnosis but developed sarcopenia preoperatively had significantly worse overall survival than patients sarcopenic at diagnosis and not sarcopenic preoperatively and patients experiencing no change in sarcopenic status (median 18 vs 47 vs 31 months; P = .02). Diagnostic and preoperative sarcopenic status alone were not significantly associated with overall survival (P = .48 and P = .56, respectively). Although 37 (52.1%) patients died, the cause of death was often not cancer-related (54.1%) and included acute respiratory failure, pneumonia, and cardiac arrest. No significant survival difference was observed when stratified by >10% weight loss (P = .9) or large loss in body mass index (P = .8).Developing sarcopenia during the neo-adjuvant period may be associated with worse overall survival in patients requiring esophagogastrectomy.Copyright © 2023 Elsevier Inc. All rights reserved.